Department of Neurology, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
First Clinical College of Wenzhou Medical University, Wenzhou, China.
Mol Neurobiol. 2024 Dec;61(12):9835-9850. doi: 10.1007/s12035-023-03638-8. Epub 2023 Sep 20.
The COVID-19 pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has resulted in devastating medical and economic consequences worldwide over the past 3 years. As the pandemic enters a new stage, it is essential to consider the potential impact on rare diseases such as Guillain-Barre syndrome (GBS), which has been intimately associated with COVID-19 since the first COVID-19-related GBS case was reported in January 2020. There are notable differences between COVID-19-related GBS and GBS without COVID-19 in terms of diagnostic types and clinical manifestations. Furthermore, with the widespread administration of COVID-19 vaccines, there have been reports of GBS occurring shortly after vaccination, which requires close attention despite its rarity. This review also explores the vaccines associated with heightened GBS risks, offering insights that may guide vaccination policies and clinical practice. To provide a visual summary of these findings, we have included a graphical abstract.
在过去的 3 年中，由严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）引起的 COVID-19 大流行在全球范围内造成了毁灭性的医疗和经济后果。随着大流行进入新阶段，必须考虑到罕见疾病（如吉兰-巴雷综合征（GBS））的潜在影响，自 2020 年 1 月报告首例与 COVID-19 相关的 GBS 病例以来，GBS 就与 COVID-19 密切相关。在诊断类型和临床表现方面，与 COVID-19 相关的 GBS 和无 COVID-19 的 GBS 之间存在显著差异。此外，随着 COVID-19 疫苗的广泛接种，有报道称接种疫苗后不久会发生 GBS，尽管这种情况很少见，但仍需要密切关注。本综述还探讨了与 GBS 风险增加相关的疫苗，为疫苗接种政策和临床实践提供了有价值的见解。为了直观地总结这些发现，我们还包括了一个图表摘要。
